The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 83 (high attention) · dilution pressure high · listing risk low · governance risk elevated · runway cash-flow positive · strongest signal: Equity line (Aug 11, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (negative equity) coexists with live selling machinery (equity line, offering (424b)). Base case is a discounted raise; the question is when, not if.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 13, 2026 | · 13D amendment | Schedule 13D/A filed 2026-08-13 filing | 24 |
| Aug 13, 2026 | · Form 4 burst | 16 Form 4 filings in 30 days filing | 18 |
| Aug 12, 2026 | · 13D amendment | Schedule 13D/A filed 2026-08-12 filing | 24 |
| Aug 11, 2026 | ▼ Equity line | “equity line” language in 8-K (EX-10.8) filed 2026-08-11 filing | 51 |
| Aug 11, 2026 | ▼ Insider selling before raise | 3 insider open-market sale(s) in the 45 days before financing filing on 2026-08-11: HHCF Series 21 Sub, LLC 612,[email protected] 2026-08-11; HHCF Series 21 Sub, LLC [email protected] 2026-08-10; HHCF Series 21 Sub, LLC [email protected] 2026-08-10 filing | 47 |
| Aug 11, 2026 | · Change in control | 8-K Item 5.01 filed 2026-08-11 (accepted 16:54 ET) filing | 42 |
| Aug 11, 2026 | ▼ Restatement (non-reliance) | “nonreliance” language in 8-K (EX-10.3) filed 2026-08-11 filing | 38 |
| Aug 11, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-11 (accepted 16:54 ET) filing | 37 |
| Aug 11, 2026 | ▼ New debt obligation | 8-K Item 2.03 filed 2026-08-11 (accepted 16:54 ET) filing | 34 |
| Aug 11, 2026 | ▼ Insider selling cluster | 3 open-market sales by 1 insider(s) (~$6,468) in 30d filing | 32 |
| Aug 11, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-08-11 (accepted 16:54 ET) filing | 22 |
| Aug 4, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-04 filing | 18 |
| Jul 27, 2026 | ▼ Offering (424B) | 424B3 prospectus supplement 2026-07-27; 1 prior 424B filings in 12m filing | 28 |
| Jun 30, 2026 | ▼ Negative equity | Stockholders' equity $-36,035,000 as of 2026-06-30 filing | 31 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · screener →